The prevalence of prediabetes in population of Polish men with late-onset hypogonadism

Figures & data

Table 1. Characteristic of patients with LOH and control group.

Parameter	LOH group No. 246	Control group No. 184	p*
Age (years)	67.3 ± 3.2	65.8 ± 3.4	NS
TT (nmol/l)	9.55 ± 1.5	16.45 ± 1.8	0.001
cfT (nmol/l)	0.323 ± 0.07	0.386 ± 0.07	0.001
DHEA (ng/mL)	2498 ± 123	2561 ± 146	NS
SHBG (nmol/L)	32.34 ± 3.1	29.5 ± 2.54	0.05
LH (mIU/l)	7.8 ± 0.34	3.4 ± 0.22	0.02
FSH (mIU/l)	5.4 ± 0.7	8.2 ± 0.7	NS
Estradiol (pg/ml)	33.7 ± 3.16	26.2 ± 3.9	0.01
BMI (kg/m2)	32.4 ± 1.4	27.6 ± 1.2	0.02
Waist circumference (cm)	108 ± 7	98 ± 6	0.05
HbA1c (%)	6.1 ± 1.2	5.4 ± 1.3	0.02
FPG (mmol/l)*	8.3 ± 0.7	5.3 ± 0.4	0.001
Systolic pressure (mmHg)	147 ± 19.2	138 ± 16.3	NS
Diastolic pressure (mmHg)	94 ± 9.2	88 ± 8.8	NS
Total cholesterol (mg/dl)	221 ± 14.5	201 ± 14.8	0.002
LDL – cholesterol (mg/dl)	155 ± 11.7	136 ± 10.7	0.02
Triglycerides (mg/dl)	177 ± 11.7	145 ± 12.5	0.05
HDL – cholesterol (mg/dl)	35.7 ± 4.3	47.4 ± 3.9	0.002

p shows differences between both groups, *in patients without T2DM.

BMI – body mass index, TT – total testosterone, cFT – calculated free testosterone, LH – luteinizing hormone, DHEA – dehydroepiandrosterone, FSH– follicle stimulating hormone, SHBG – sex hormone binding globuline, FPG – fasting plasma glucose.

Figure 1. The prevalence (%) of normoglycemia, prediabetes and T2DM in patients with LOH and in control group. T2DM – diabetes mellitus type 2.

Table 2. Total and free testosterone concentrations in the LOH group after dividing according to glycemic control disorders.

		Prediabetes
Parameter	T2DM (n = 25)	All (n = 102)	IFG (n = 60)	IGT (n = 56)	HbA1c 5.7–6.4% (n = 92)	Normoglycemia (n = 121)	p*
TT (nmol/l)	8.23 ± 1.2	9.3 ± 0.9	9.2 ± 1.1	8.7 ± 1.2**	9.5 ± 1.3	10.6 ± 1.2	0.02
cFT (nmol/l)	0.231. ± 0.07	0.287 ± 0.08	0.278 ± 0.07	0.262 ± 0.06	0.292 ± 0.08	0.375 ± 0.07	0.002

*p shows differences between prediabetic and normoglycemic patients in the LOH group.

**p < 0.005 between patients with IGT and all prediabetic patients in the LOH group.

TT – total testosterone, cFT – calculated free testosterone.

Table 3. Comorbidities (no.pts.;%) in all LOH patients, prediabetic and normoglycemic subgroup and in the control group.

Parameter	All LOH group n = 246	Prediabetic n = 102	Normoglycemic n = 120	Control group n = 184	p*
Obesity	140 (57)	62 (61)	49 (41)	58 (32)	0.002
Current smoker	76 (31)	34 (33)	36 (30)	61 (33)	NS
Hypertension	124 (50)	46 (45)	60 (50)	92 (50)	NS
MetS	162 (66)	66 (65)	68 (56)	96 (52)	0.02
CVD	72 (29)	33 (32)	32 (27)	41 (22)	0.05

*p shows significant differences between LOH and control group.

MetS – metabolic syndrome, CVD – cardiovascular disease.